August 2015: AWMSG approvals
The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): brimonidine gel for treating the symptoms of moderate-to-severe, persistent facial erythema associated with rosacea; Rezolsta (darunavir and cobicistat) for use in combination with other antiretroviral medicines to treat human immunodeficiency virus-1 infection in adults; magnesium aspartate dihydrate for treating and preventing magnesium deficiency in patients aged two years and over; Envarsus (tacrolimus) for preventing transplant rejection in adult recipients of kidney or liver allografts, and for treating allograft rejection, which is resistant to other immunosuppressive medicines, in adults; and pomalidomide for use with dexamethasone to treat relapsed and refractory multiple myeloma in adults who have received at least two prior treatment regimens — including both lenalidomide and bortezomib — and have demonstrated disease progression on the most recent treatment. This recommendation applies only if the approved patient access scheme is used. Full details of restrictions are available from the AWMSG website.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069260
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com